Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tai Tien Pharmaceuticals, a consolidated subsidiary of Mitsubishi Tanabe Pharma, has launched Simponi solution for injection, to treat rheumatoid arthritis and ankylosing spondylitis, in Taiwan.
Subscribe to our email newsletter
Simponi solution for injection is a human TNFa monoclonal antibody, golimumab.
Simponi was discovered and developed by Jansen Biotech as a treatment for inflammatory autoimmune diseases (involving TNFa) such as rheumatoid arthritis.
In July 2011, Jansen received marketing and manufacturing license of the product, after which Jansen and Mitsubishi started co-marketing the agent.
Jansan Taiwan will also be marketing Simponi solution for injection along with Mitsubishi, in Taiwan.